Physician profile
Alan Cheung
NPI 1235283391
$10,281.65
in general payments reported to CMS, 2019-2025
16 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $595 · 2021: $908 · 2022: $2,588 · 2023: $1,596 · 2024: $1,640 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,303.99 | 2022-2025 | Infuse, Btod, Biotrue One Day |
| Alcon Vision LLC | $1,616.92 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $1,587.36 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $1,439.66 | 2019-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $1,255.34 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $829.16 | 2019-2021 | |
| Menicon America INC | $373.58 | 2019-2022 | |
| Oyster Point Pharma, INC. | $263.59 | 2022 | |
| Glaukos Corporation | $209.07 | 2025 | Kxl System (Not Refurbished) |
| Sight Sciences, INC. | $124.98 | 2019 | |
| Abbvie INC. | $122.65 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $39.10 | 2024 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $33.07 | 2019 | |
| Allergan, INC. | $32.88 | 2019-2022 | |
| Biotissue Holdings INC. | $29.45 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $20.85 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.